GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D. Western Therapeutics Institute Inc (TSE:4576) » Definitions » Cash-to-Debt

D. Western Therapeutics Institute (TSE:4576) Cash-to-Debt : 1.41 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is D. Western Therapeutics Institute Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. D. Western Therapeutics Institute's cash to debt ratio for the quarter that ended in Dec. 2024 was 1.41.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, D. Western Therapeutics Institute could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for D. Western Therapeutics Institute's Cash-to-Debt or its related term are showing as below:

TSE:4576' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.41   Med: 3.38   Max: No Debt
Current: 1.41

During the past 13 years, D. Western Therapeutics Institute's highest Cash to Debt Ratio was No Debt. The lowest was 1.41. And the median was 3.38.

TSE:4576's Cash-to-Debt is ranked worse than
72.19% of 1485 companies
in the Biotechnology industry
Industry Median: 7.49 vs TSE:4576: 1.41

D. Western Therapeutics Institute Cash-to-Debt Historical Data

The historical data trend for D. Western Therapeutics Institute's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

D. Western Therapeutics Institute Cash-to-Debt Chart

D. Western Therapeutics Institute Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.02 5.69 2.41 2.11 1.41

D. Western Therapeutics Institute Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.47 2.11 1.40 1.17 1.41

Competitive Comparison of D. Western Therapeutics Institute's Cash-to-Debt

For the Biotechnology subindustry, D. Western Therapeutics Institute's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


D. Western Therapeutics Institute's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where D. Western Therapeutics Institute's Cash-to-Debt falls into.


;
;

D. Western Therapeutics Institute Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

D. Western Therapeutics Institute's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

D. Western Therapeutics Institute's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


D. Western Therapeutics Institute  (TSE:4576) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


D. Western Therapeutics Institute Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of D. Western Therapeutics Institute's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


D. Western Therapeutics Institute Business Description

Traded in Other Exchanges
N/A
Address
7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.

D. Western Therapeutics Institute Headlines

No Headlines